Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/04/2022* -- Results Q3 2022 -- -1.06 --
11/04/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
08/04/2022 -- Results Q2 2022 -1.00 -0.97 -2.67%
08/04/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/05/2022 -- Results Q1 2022 -0.91 -1.10 17.46%
05/05/2022 16:30 EST Earnings Call Q1 2022 -- -- --
02/23/2022 -- Results Q4 2021 -1.15 -1.08 -6.09%
02/23/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/04/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/04/2022
Beat/Miss Upgrade
Return Since 7.32%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
URL https://www.guardanthealth.com
Investor Relations URL https://investors.guardanthealth.com/
HQ State/Province California
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Blend
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
--
--
--
107.9%
64.93%
-22.39%
-45.18%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.90%
-66.36%
44.75%
293.3%
20.10%
46.56%
43.26%
-41.26%
-57.21%
3.99%
-33.29%
70.64%
37.27%
10.61%
11.53%
2.82%
-50.78%
--
--
--
--
--
54.43%
18.78%
-24.79%
-58.68%
-88.50%
-99.97%
-99.39%
-89.16%
-15.67%
-56.75%
-57.81%
As of October 03, 2022.

Profile

Edit
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company’s pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
URL https://www.guardanthealth.com
Investor Relations URL https://investors.guardanthealth.com/
HQ State/Province California
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Blend
Next Earnings Release Nov. 04, 2022 (est.)
Last Earnings Release Aug. 04, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
F00001DMS4 408.00 USD 4.08%
F00001EGLI 342.00 USD 3.42%
F00001DYDB 258.00 USD 2.58%
ETCHX 30.30M USD 2.29%
HTEC 1.581M USD 1.59%
HQH 11.50M USD 1.13%
IHF 16.55M USD 1.07%
FPHAX 8.629M USD 0.98%
BBH 3.902M USD 0.92%
HQL 4.455M USD 0.91%
ISCG 1.237M USD 0.35%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter GH Tweets